Calidi Biotherapeutics

#ICYMI: $CLDI's CEO Eric Poma, Ph.D. spoke with BioPharma Boardroom about the #RedTail platform, CLD-401 and Calidi’s approach to reaching primary and metastatic tumors. 🔗: bit.ly/4vXCQw5

In a recent Talking Biotech episode, $CLDI's CEO & Director Eric Poma, Ph.D. discusses Calidi’s systemic #oncolyticvirus platform and CLD-401, designed to avoid immune clearance and selectively replicate in tumor cells. Listen on @ApplePodcasts: apple.co/3Vfxhg4

In a interview with @RedChip Eric Poma, Ph.D. discusses $CLDI's #RedTail platform & CLD-401, designed to target and lyse tumor cells while delivering an IL-15 superagonist to help activate an anti-cancer immune response. Watch the clip & full interview: bit.ly/3T59XQ

$CLDI shared preclinical #RedTail data at‌ @myESMO's #ESMO26. A single dose of CLD-401 achieved complete tumor eradication in 80% of mice, while the in situ TCE platform generated ~10 ng/mL of EpCAM-targeted TCE directly in tumors after IV delivery. 🔗 bit.ly/4dXjKQS

Advancing a new generation of cancer therapies at $CLDI. Targeted delivery. Immune activation. Real impact. The future of cancer care is bigger than one approach. Learn more about our science: bit.ly/4d89lR5 #Oncology

$CLDI will present new preclinical data from its RedTail platform at @myESMO's conference in Madrid. On October 24, Calidi will share new CLD-401 data and advances from its in situ T-cell engager platform, including CLD-501 and CLD-502. 🔗: bit.ly/4z2PJHQ #ESMO26

$CLDI's CEO Eric Poma, Ph.D. joined @kevinfolta to discuss the potential of #oncolyticviruses for solid tumors and Calidi’s vaccinia-based approach designed to reach tumors and stimulate an immune response. Listen on @ApplePodcasts: apple.co/3Vfxhg4 #Oncology,

$CLDI’s CLD-401 is designed to home to metastatic tumor sites, induce tumor cell lysis and immune priming, and support local production of an IL-15 superagonist to help generate an anti-tumor immune response. Learn more about our science: bit.ly/4d89lR5

This #WorldCancerResearchDay, $CLDI honors the researchers, clinicians and innovators advancing new approaches for patients with cancer. Continued research is essential to creating new possibilities and improving the future of cancer care. #CancerResearch

Earlier this month, $CLDI's CEO Eric Poma, Ph. shared his perspective with Drug Discovery Online on the future of cancer drug discovery and targeted immune activation. Read more: bit.ly/4iFtPVt

In this #NanoCapPodcast clip, $CLDI's CEO Eric Poma discusses progress toward an #IND application and plans to begin clinical studies following the regulatory process. Watch the clip and listen to the full episode here: bit.ly/4gumW83

What is an IL-15 superagonist, and how does it connect to $CLDI’s lead program, CLD-401? CLD-401 is designed to produce IL-15 superagonist at the tumor, helping activate immune cells and support an anti-tumor immune response.

Meet Antonio F. Santidrian, PharmD, Ph.D., CSO and Head of Technical Operations at $CLDI. Since joining Calidi in 2015, Antonio has led R&D and is a coinventor of the RedTail Platform, bringing 20+ years of anti-cancer translational research experience.

$CLDI’s CEO, Eric Poma, Ph.D., will hold one-on-one meetings with investors at @HCWCO's 28th Annual Global Investment Conference. A virtual presentation will be available on-demand for registered attendees via the conference platform starting 9/11/26. 🔗 bit.ly/3SOk1hC

Today we're spotlighting $CLDI's Board of Directors, whose expertise spans biotechnology, clinical development, and corporate leadership. Learn more: bit.ly/4g36fAJ #BoardOfDirectors

August is #WorldCancerSupportMonth. $CLDI recognizes the strength of patients, caregivers, healthcare professionals, and advocates while continuing to advance innovative targeted genetic medicines for the future of #cancercare.

Following last week's Q2 update, $CLDI continues to advance its RedTail platform and pipeline. Q2 highlights included regulatory progress for CLD-401, new platform data and progress toward first patient dosing in Q1 2027. 🔗: bit.ly/4qqfL47 #Biotech